asparaginase

Type: Keyphrase
Name: asparaginase
First reported Aug 27 2014 - Updated Aug 28 2014 - 1 reports

ERYTECH Announces Second Positive DSMB Review of Its Phase IIb Study in Acute Myeloid Leukemia

Regulatory News:ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP),the French biopharmaceutical company that develops innovative ‘tumorstarvation’ treatments for acute leukemia and other oncology indicationswith unmet medical needs, announces ... [Published Crawford Financial Planning - Aug 27 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 2 reports

Jazz Pharmaceuticals Announces Agreement To Acquire Rights To Defibrotide In The Americas From Sigma-Tau Pharmaceuticals, Inc.

Press Release   View printer-friendly version <<  Back   Download PDF Jazz Pharmaceuticals to own worldwide rights to defibrotide at closingInvestor conference call to be held today, July 2 at 8:30 AM EDT/1:30 PM ISTDUBLIN , July 2, 2014  /PRNewswire/ ... [Published Longitude Capital - Aug 19 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 2 reports

How to Solve Big Problems: Start Small

In late November of 1991, a three-year-old girl was diagnosed with leukemia. There was a 30 percent chance she would die.In the coming months, she would receive a long list of chemotherapy drugs: 6MP, asparaginase, methotrexate, prednisone, and vincrinstine. ... [Published DailyMe.Com - Aug 18 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

Jazz Pharmaceuticals Announces Pricing of $500 Million of Exchangeable Senior Notes

DUBLIN, Aug. 8, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), priced its previously announced offering of $500 million aggregate principal amount ... [Published BusinessWeek - Aug 08 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

Study Modification: Asparaginase hypersensitivity in acute lymphoblastic leukemia

AUTHOR: Chen SHSTUDY DATE: June 30, 2010TITLE: Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. ... [Published National Human Genome Research Institute - Aug 08 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

ERYTECH PHARMA : announces enrollment of first patient in Phase II study of ERY-ASP in pancreatic cancer

PRESS RELEASE ERYTECH announces enrollment of first patient in Phase II study of ERY-ASP in pancreatic cancerLyon (France), July 28, 2014 - ERYTECH Pharma (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ... [Published 4 Traders - Aug 07 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Jazz Pharmaceuticals Announces Proposed Offering of $500 Million of Exchangeable Senior Notes

DUBLIN, Aug. 6, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), intends to offer, subject to market conditions and other factors, $500 million aggregate ... [Published TickerTech.com - Aug 06 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Jazz Pharmaceuticals' (JAZZ) CEO Bruce Cozadd on Q2 2014 Results - Earnings Call Transcript

OperatorGood day ladies and gentlemen and welcome to the Jazz Pharmaceuticals Second Quarter 2014 Earnings Conference Call. Following an introduction from the company, we will open the call to questions.I'll now turn the call over to Kathy Littrell, Head ... [Published Seeking Alpha - Aug 06 2014]
First reported Aug 04 2014 - Updated Aug 05 2014 - 1 reports

Jazz Pharmaceuticals Announces Participation at Canaccord Genuity Conference on August 13

DUBLIN, Aug. 4, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the Canaccord Genuity 34th Annual Growth Conference in Boston, MA on Wednesday, August 13, 2014 ... [Published BusinessWeek - Aug 04 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology"

/PRNewswire/ -- The Galien Foundation today announced the 2014 nominees for the eighth annual Prix Galien USA Awards. The Prix Galien Award is considered the biomedical industry's highest accolade and recognizes the technical, scientific and clinical ... [Published TickerTech.com - Jul 31 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

Studies from Department of Biotechnology Add New Findings in the Area of Leukemia (Plant asparaginase-based asparagine biosensor for leukemia)

By a News Reporter-Staff News Editor at Biotech Week -- Investigators discuss new findings in Oncology. According to news reporting from Patiala, India , by NewsRx journalists, research stated, "The present work aims at the development of plant asparaginase-based ... [Published HispanicBusiness.com - Jul 31 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Jazz Pharmaceuticals to Report 2014 Second Quarter Financial Results on August 5, 2014

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2014 second quarter financial results on Tuesday, August 5, 2014, after the close of the financial markets. Company management will host a live audio webcast ... [Published TickerTech.com - Jul 22 2014]

Quotes

...clinical and commercial expertise in hematology/oncology," said Bruce Cozadd , chairman and chief executive officer of Jazz Pharmaceuticals plc . "This transaction supports our mission to improve care for patients with serious medical conditions, and we remain committed to making targeted investments to develop and bring to market differentiated treatments for patients."
...of clozapine that is FDA approved to treat this difficult condition," said Bruce C Cozadd , chairman and CEO at Jazz Pharmaceuticals plc .   "Versacloz is an important addition to our existing psychiatry product portfolio and offers physicians another treatment option to help patients with limited treatment options."
"Severe VOD is a complex and unpredictable disease, and its impact on patients, physicians and resources is substantial.  Early and effective intervention is crucial in saving lives and limiting the potentially significant burden of this disease, and physicians have been eagerly awaiting the commercial availability of Defitelio in Europe " said Professor Mohamad Mohty , President-Elect of the EBMT and Professor of Haematology, Saint-Antoine Hospital and University Pierre & Marie Curie...
"New drugs for the second line treatment of pancreatic cancer are strongly needed. Starving the tumors in amino acid thanks to ERY-ASP is an innovative and promising approach. I am happy this study is started " says Professor Pascal Hammel, Principal investigator of the study, Department of Gastroenterology & Pancreatology at Hopital Beaujon (Clichy- France...

More Content

All (26) | News (24) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
ERYTECH Announces Second Positive DSMB Review o... [Published Crawford Financial Planning - Aug 27 2014]
Jazz Pharmaceuticals Announces Agreement To Acq... [Published Longitude Capital - Aug 19 2014]
Jazz Pharmaceuticals Announces U.S. Commercial ... [Published Longitude Capital - Aug 19 2014]
Jazz Pharmaceuticals And Gentium Announce Europ... [Published Longitude Capital - Aug 19 2014]
How to Solve Big Problems: Start Small [Published DailyMe.Com - Aug 18 2014]
How to Solve Big Problems: Start Small [Published Entrepreneur.com - Aug 18 2014]
Jazz Pharmaceuticals Announces Pricing of $500 ... [Published BusinessWeek - Aug 08 2014]
Study Modification: Asparaginase hypersensitivi... [Published National Human Genome Research Institute - Aug 08 2014]
ERYTECH PHARMA : announces enrollment of first ... [Published 4 Traders - Aug 07 2014]
ERYTECH PHARMA : Reports Phase II Study of ERY-ASP [Published 4 Traders - Aug 07 2014]
Jazz Pharmaceuticals Announces Proposed Offerin... [Published TickerTech.com - Aug 06 2014]
Jazz Pharmaceuticals' (JAZZ) CEO Bruce Cozadd o... [Published Seeking Alpha - Aug 06 2014]
Jazz Pharmaceuticals Announces Second Quarter 2... [Published TickerTech.com - Aug 05 2014]
Jazz Pharmaceuticals Completes Acquisition Of R... [Published ADVFN India - Aug 05 2014]
Jazz Pharmaceuticals Announces Participation at... [Published BusinessWeek - Aug 04 2014]
The Galien Foundation Announces 2014 Prix Galie... [Published TickerTech.com - Jul 31 2014]
Studies from Department of Biotechnology Add Ne... [Published HispanicBusiness.com - Jul 31 2014]
Jazz Pharmaceuticals to Report 2014 Second Quar... [Published TickerTech.com - Jul 22 2014]
MicroRNA-140-5p as a tumor suppressor and sensi... [Published PharmCast - Jul 18 2014]
Research and Markets: Baking Enzymes Market 201... [Published Business Wire Retail News - May 20 2014]
Compositions and methods for delivering inhibit... [Published PharmCast - May 08 2014]
Erytech receives ANSM authorisation to begin ph... [Published PharmaBiz - May 07 2014]
Tumor-initiating cells and methods of use [Published PharmCast - Apr 09 2014]
Delivery system for cytotoxic drugs by bispecif... [Published PharmCast - Mar 02 2014]
Jazz Pharmaceuticals Announces Acquisition From... [Published PR Newswire - Jan 13 2014]
Methods and compositions for targeting agents i... [Published PharmCast - Jan 05 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Research and Markets: Baking Enzymes Market 201... [Published Business Wire Retail News - May 20 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/8tqx89/baking_enzymes) has announced the addition of the "Baking Enzymes Market by Geography, Types & Application- Global Trends & Forecasts to 2019" report to their ...
1

Press Releases

sort by: Date | Relevance
Jazz Pharmaceuticals Announces Acquisition From... [Published PR Newswire - Jan 13 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.